Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 87

Cited In for PubMed (Select 16785475)

1.

Experience with subcutaneous abatacept for rheumatoid arthritis: an update for clinicians.

Khraishi MM.

Ther Adv Musculoskelet Dis. 2014 Oct;6(5):159-68. doi: 10.1177/1759720X14551567. Review.

2.

Biologic-free remission of established rheumatoid arthritis after discontinuation of abatacept: a prospective, multicentre, observational study in Japan.

Takeuchi T, Matsubara T, Ohta S, Mukai M, Amano K, Tohma S, Tanaka Y, Yamanaka H, Miyasaka N.

Rheumatology (Oxford). 2015 Apr;54(4):683-91. doi: 10.1093/rheumatology/keu338. Epub 2014 Sep 24.

3.

Effect of combination therapy on joint destruction in rheumatoid arthritis: a network meta-analysis of randomized controlled trials.

Graudal N, Hubeck-Graudal T, Tarp S, Christensen R, Jürgens G.

PLoS One. 2014 Sep 22;9(9):e106408. doi: 10.1371/journal.pone.0106408. eCollection 2014. Review.

4.

Efficacy and safety of abatacept for patients with Sjögren's syndrome associated with rheumatoid arthritis: rheumatoid arthritis with orencia trial toward Sjögren's syndrome Endocrinopathy (ROSE) trial-an open-label, one-year, prospective study-Interim analysis of 32 patients for 24 weeks.

Tsuboi H, Matsumoto I, Hagiwara S, Hirota T, Takahashi H, Ebe H, Yokosawa M, Hagiya C, Asashima H, Takai C, Miki H, Umeda N, Kondo Y, Ogishima H, Suzuki T, Hirata S, Saito K, Tanaka Y, Horai Y, Nakamura H, Kawakami A, Sumida T.

Mod Rheumatol. 2015 Mar;25(2):187-93. doi: 10.3109/14397595.2014.951144. Epub 2014 Sep 11.

6.

Tocilizumab in the treatment of rheumatoid arthritis: a cost-effectiveness analysis in the UK.

Diamantopoulos A, Finckh A, Huizinga T, Sungher DK, Sawyer L, Neto D, Dejonckheere F.

Pharmacoeconomics. 2014 Aug;32(8):775-87. doi: 10.1007/s40273-014-0165-7.

7.

Treatment comparison in rheumatoid arthritis: head-to-head trials and innovative study designs.

Favalli EG, Bugatti S, Biggioggero M, Caporali R.

Biomed Res Int. 2014;2014:831603. doi: 10.1155/2014/831603. Epub 2014 Apr 16. Review.

8.

Efficacy and safety of infliximab-biosimilar compared to other biological drugs in rheumatoid arthritis: a mixed treatment comparison.

Baji P, Péntek M, Czirják L, Szekanecz Z, Nagy G, Gulácsi L, Brodszky V.

Eur J Health Econ. 2014 May;15 Suppl 1:S53-64. doi: 10.1007/s10198-014-0594-4. Epub 2014 May 16. Review.

9.

Comparative clinical utility of once-weekly subcutaneous abatacept in the management of rheumatoid arthritis.

Rakieh C, Conaghan PG.

Ther Clin Risk Manag. 2014 Apr 30;10:313-20. doi: 10.2147/TCRM.S60740. eCollection 2014. Review.

10.

Long-term safety of subcutaneous abatacept in rheumatoid arthritis: integrated analysis of clinical trial data representing more than four years of treatment.

Alten R, Kaine J, Keystone E, Nash P, Delaet I, Genovese MC.

Arthritis Rheumatol. 2014 Aug;66(8):1987-97. doi: 10.1002/art.38687.

11.

Abatacept for the treatment of rheumatoid arthritis: A review.

Kaine JL.

Curr Ther Res Clin Exp. 2007 Nov;68(6):379-99. doi: 10.1016/j.curtheres.2007.12.001.

12.

Mavrilimumab: an evidence based review of its potential in the treatment of rheumatoid arthritis.

Di Franco M, Gerardi MC, Lucchino B, Conti F.

Core Evid. 2014 Mar 12;9:41-8. doi: 10.2147/CE.S39770. eCollection 2014. Review.

13.

A critical evaluation of the role of subcutaneous abatacept in the treatment of rheumatoid arthritis: patient considerations.

Wells AF, Jodat N, Schiff M.

Biologics. 2014 Feb 17;8:41-55. doi: 10.2147/BTT.S55783. eCollection 2014. Review.

14.

Real-world effectiveness of abatacept for rheumatoid arthritis treatment in European and Canadian populations: a 6-month interim analysis of the 2-year, observational, prospective ACTION study.

Nüßlein HG, Alten R, Galeazzi M, Lorenz HM, Boumpas D, Nurmohamed MT, Bensen WG, Burmester GR, Peter HH, Rainer F, Pavelka K, Chartier M, Poncet C, Rauch C, Bars ML.

BMC Musculoskelet Disord. 2014 Jan 11;15:14. doi: 10.1186/1471-2474-15-14.

15.

Non-tumor necrosis factor-based biologic therapies for rheumatoid arthritis: present, future, and insights into pathogenesis.

Paula FS, Alves JD.

Biologics. 2014;8:1-12. doi: 10.2147/BTT.S35475. Epub 2013 Dec 9. Review.

16.

Efficacy of abatacept for arthritis in patients with an overlap syndrome between rheumatoid arthritis and systemic lupus erythematosus.

Ikeda K, Sanayama Y, Makita S, Hosokawa J, Yamagata M, Nakagomi D, Takabayashi K, Nakajima H.

Clin Dev Immunol. 2013;2013:697525. doi: 10.1155/2013/697525. Epub 2013 Nov 14.

17.

The comparative effectiveness of abatacept versus anti-tumour necrosis factor switching for rheumatoid arthritis patients previously treated with an anti-tumour necrosis factor.

Harrold LR, Reed GW, Kremer JM, Curtis JR, Solomon DH, Hochberg MC, Greenberg JD.

Ann Rheum Dis. 2015 Feb;74(2):430-6. doi: 10.1136/annrheumdis-2013-203936. Epub 2013 Dec 2.

18.

Rheumatoid arthritis and cardiovascular disease.

Crowson CS, Liao KP, Davis JM 3rd, Solomon DH, Matteson EL, Knutson KL, Hlatky MA, Gabriel SE.

Am Heart J. 2013 Oct;166(4):622-628.e1. doi: 10.1016/j.ahj.2013.07.010. Epub 2013 Aug 29. Review.

19.

Clinical efficacy of abatacept compared to adalimumab and tocilizumab in rheumatoid arthritis patients with high disease activity.

Takahashi N, Kojima T, Kaneko A, Kida D, Hirano Y, Fujibayashi T, Yabe Y, Takagi H, Oguchi T, Miyake H, Kato T, Fukaya N, Ishikawa H, Hayashi M, Tsuboi S, Kanayama Y, Kato D, Funahashi K, Matsubara H, Hattori Y, Hanabayashi M, Hirabara S, Terabe K, Yoshioka Y, Ishiguro N.

Clin Rheumatol. 2014 Jan;33(1):39-47. doi: 10.1007/s10067-013-2392-2. Epub 2013 Sep 22.

20.

Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: two-year efficacy and safety findings from AMPLE trial.

Schiff M, Weinblatt ME, Valente R, van der Heijde D, Citera G, Elegbe A, Maldonado M, Fleischmann R.

Ann Rheum Dis. 2014 Jan;73(1):86-94. doi: 10.1136/annrheumdis-2013-203843. Epub 2013 Aug 20.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk